Expression of CXCR3 on specific T cells is essential for homing to the prostate gland in an experimental model of chronic prostatitis/chronic pelvic pain syndrome

Journal of Immunology

Volumn 190, Issue 7, 2013, Pages 3121-3133

  Breser, Maria L ^a   Motrich, Ruben D ^a   Sanchez, Leonardo R ^a   Mackern Oberti, Juan P ^a   Rivero, Virginia E ^a  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR3 LIGAND; GAMMA INTERFERON; LIGAND; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CHRONIC PELVIC PAIN SYNDROME; CHRONIC PROSTATITIS; CONTROLLED STUDY; CXCR3+ CD3+ T LYMPHOCYTE; DISEASE PREDISPOSITION; EFFECTOR CELL; EXPERIMENTAL MODEL; LYMPHOCYTE HOMING; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PELVIS PAIN SYNDROME; PHENOTYPE; PRIORITY JOURNAL; PROSTATE; PROTEIN EXPRESSION; STRAIN DIFFERENCE; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TISSUE LEVEL;

ANIMALS; AUTOIMMUNE DISEASES; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; INTERFERON-GAMMA; MALE; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; PROSTATE; PROSTATITIS; RECEPTORS, CHEMOKINE; RECEPTORS, CXCR3; T-LYMPHOCYTE SUBSETS; TH1 CELLS; TH17 CELLS;

EID: 84875479909     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202482     Document Type: Article

References (46)

1. Collins, M. M., R. S. Stafford, M. P. O'Leary, and M. J. Barry. 1998. How common is prostatitis? A national survey of physician visits. J. Urol. 159: 1224-1228.
2. Schaeffer, A. J. 2006. Clinical practice. Chronic prostatitis and the chronic pelvic pain syndrome. N. Engl. J. Med. 355: 1690-1698.
3. Krieger, J. N., L. Nyberg, Jr., and J. C. Nickel. 1999. NIH consensus definition and classification of prostatitis. JAMA 282: 236-237.
4. Rivero, V. E., R. D. Motrich, M. Maccioni, and C. M. Riera. 2007. Autoimmune etiology in chronic prostatitis syndrome: an advance in the understanding of this pathology. Crit. Rev. Immunol. 27: 33-46.
5. Motrich, R. D., M. Maccioni, R. Molina, A. Tissera, J. Olmedo, C. M. Riera, and V. E. Rivero. 2005. Presence of INFgamma-secreting lymphocytes specific to prostate antigens in a group of chronic prostatitis patients. Clin. Immunol. 116: 149-157.
6. Alexander, R. B., F. Brady, and S. Ponniah. 1997. Autoimmune prostatitis: evidence of T cell reactivity with normal prostatic proteins. Urology 50: 893-899.
7. Batstone, G. R., A. Doble, and J. S. Gaston. 2002. Autoimmune T cell responses to seminal plasma in chronic pelvic pain syndrome (CPPS). Clin. Exp. Immunol. 128: 302-307.
8. Hou, Y., J. DeVoss, V. Dao, S. Kwek, J. P. Simko, D. G. McNeel, M. S. Anderson, and L. Fong. 2009. An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans. J. Clin. Invest. 119: 2031-2041.
9. Alexander, R. B., S. Ponniah, J. Hasday, and J. R. Hebel. 1998. Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome. Urology 52: 744-749.
10. Nadler, R. B., A. E. Koch, E. A. Calhoun, P. L. Campbell, D. L. Pruden, C. L. Bennett, P. R. Yarnold, and A. J. Schaeffer. 2000. IL-1beta and TNF-alpha in prostatic secretions are indicators in the evaluation of men with chronic prostatitis. J. Urol. 164: 214-218.
11. Motrich, R. D., M. Maccioni, R. Molina, A. Tissera, J. Olmedo, C. M. Riera, and V. E. Rivero. 2005. Reduced semen quality in chronic prostatitis patients that have cellular autoimmune response to prostate antigens. Hum. Reprod. 20: 2567-2572.
12. John, H., A. Barghorn, G. Funke, T. Sulser, S. Hailemariam, D. Hauri, and H. Joller-Jemelka. 2001. Noninflammatory chronic pelvic pain syndrome: immunological study in blood, ejaculate and prostate tissue. Eur. Urol. 39: 72-78.
13. Motrich, R. D., M. Maccioni, C. M. Riera, and V. E. Rivero. 2007. Autoimmune prostatitis: state of the art. Scand. J. Immunol. 66: 217-227.
14. Rivero, V. E., C. Cailleau, M. Depiante-Depaoli, C. M. Riera, and C. Carnaud. 1998. Non-obese diabetic (NOD) mice are genetically susceptible to experimental autoimmune prostatitis (EAP). J. Autoimmun. 11: 603-610.
15. Motrich, R. D., M. Maccioni, A. A. Ponce, G. A. Gatti, J. P. Oberti, and V. E. Rivero. 2006. Pathogenic consequences in semen quality of an autoimmune response against the prostate gland: from animal models to human disease. J. Immunol. 177: 957-967.
16. Rudick, C. N., A. J. Schaeffer, and P. Thumbikat. 2008. Experimental autoimmune prostatitis induces chronic pelvic pain. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294: R1268-R1275.
17. Keetch, D. W., P. Humphrey, and T. L. Ratliff. 1994. Development of a mouse model for nonbacterial prostatitis. J. Urol. 152: 247-250.
18. Penna, G., S. Amuchastegui, C. Cossetti, F. Aquilano, R. Mariani, N. Giarratana, E. De Carli, B. Fibbi, and L. Adorini. 2007. Spontaneous and prostatic steroid binding protein peptide-induced autoimmune prostatitis in the nonobese diabetic mouse. J. Immunol. 179: 1559-1567.
19. Motrich, R. D., E. van Etten, F. Baeke, C. M. Riera, C. Mathieu, and V. E. Rivero. 2010. Crucial role of interferon-g in experimental autoimmune prostatitis. J. Urol. 183: 1213-1220.
20. Peters, A., Y. Lee, and V. K. Kuchroo. 2011. The many faces of Th17 cells. Curr. Opin. Immunol. 23: 702-706.
21. Ward, S. G., and F. M. Marelli-Berg. 2009. Mechanisms of chemokine and antigen-dependent T-lymphocyte navigation. Biochem. J. 418: 13-27.
22. Kunkel, E. J., and E. C. Butcher. 2002. Chemokines and the tissue-specific migration of lymphocytes. Immunity 16: 1-4.
23. Bono, M. R., R. Elgueta, D. Sauma, K. Pino, F. Osorio, P. Michea, A. Fierro, and M. Rosemblatt. 2007. The essential role of chemokines in the selective regulation of lymphocyte homing. Cytokine Growth Factor Rev. 18: 33-43.
24. McGeachy, M. J., K. S. Bak-Jensen, Y. Chen, C. M. Tato, W. Blumenschein, T. McClanahan, and D. J. Cua. 2007. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat. Immunol. 8: 1390-1397.
25. Ni, J., Y. N. Zhu, X. G. Zhong, Y. Ding, L. F. Hou, X. K. Tong, W. Tang, S. Ono, Y. F. Yang, and J. P. Zuo. 2009. The chemokine receptor antagonist, TAK-779, decreased experimental autoimmune encephalomyelitis by reducing inflammatory cell migration into the central nervous system, without affecting T cell function. Br. J. Pharmacol. 158: 2046-2056.
26. Suzaki, Y., K. Hamada, T. Nomi, T. Ito, M. Sho, Y. Kai, Y. Nakajima, and H. Kimura. 2008. A small-molecule compound targeting CCR5 and CXCR3 prevents airway hyperresponsiveness and inflammation. Eur. Respir. J. 31: 783-789.
27. Sallusto, F., and A. Lanzavecchia. 2009. Heterogeneity of CD4+ memory T cells: functional modules for tailored immunity. Eur. J. Immunol. 39: 2076-2082.
28. Cox, C. A., G. Shi, H. Yin, B. P. Vistica, E. F. Wawrousek, C. C. Chan, and I. Gery. 2008. Both Th1 and Th17 are immunopathogenic but differ in other key biological activities. J. Immunol. 180: 7414-7422.
29. Emamaullee, J. A., J. Davis, S. Merani, C. Toso, J. F. Elliott, A. Thiesen, and A. M. Shapiro. 2009. Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 58: 1302-1311.
30. Bending, D., H. De la Peña, M. Veldhoen, J. M. Phillips, C. Uyttenhove, B. Stockinger, and A. Cooke. 2009. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J. Clin. Invest. 119: 565-572.
31. Jankovic, D., and G. Trinchieri. 2007. IL-10 or not IL-10: that is the question. Nat. Immunol. 8: 1281-1283.
32. Martin-Orozco, N., Y. Chung, S. H. Chang, Y. H. Wang, and C. Dong. 2009. Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur. J. Immunol. 39: 216-224.
33. Lau, K., P. Benitez, A. Ardissone, T. D. Wilson, E. L. Collins, G. Lorca, N. Li, D. Sankar, C. Wasserfall, J. Neu, et al. 2011. Inhibition of type 1 diabetes correlated to a Lactobacillus johnsonii N6.2-mediated Th17 bias. J. Immunol. 186: 3538-3546.
34. Nikoopour, E., J. A. Schwartz, K. Huszarik, C. Sandrock, O. Krougly, E. Lee-Chan, and B. Singh. 2010. Th17 polarized cells from nonobese diabetic mice following mycobacterial adjuvant immunotherapy delay type 1 diabetes. J. Immunol. 184: 4779-4788.
35. Tse, H. M., T. C. Thayer, C. Steele, C. M. Cuda, L. Morel, J. D. Piganelli, and C. E. Mathews. 2010. NADPH oxidase deficiency regulates Th lineage commitment and modulates autoimmunity. J. Immunol. 185: 5247-5258.
36. Joseph, J., S. Bittner, F. M. Kaiser, H. Wiendl, and S. Kissler. 2012. IL-17 silencing does not protect nonobese diabetic mice from autoimmune diabetes. J. Immunol. 188: 216-221.
37. Kriegel, M. A., E. Sefik, J. A. Hill, H. J. Wu, C. Benoist, and D. Mathis. 2011. Naturally transmitted segmented filamentous bacteria segregate with diabetes protection in nonobese diabetic mice. Proc. Natl. Acad. Sci. USA 108: 11548-11553.
38. O'Connor, W., Jr., M. Kamanaka, C. J. Booth, T. Town, S. Nakae, Y. Iwakura, J. K. Kolls, and R. A. Flavell. 2009. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat. Immunol. 10: 603-609.
39. Liu, M., S. Guo, J. M. Hibbert, V. Jain, N. Singh, N. O. Wilson, and J. K. Stiles. 2011. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev. 22: 121-130.
40. Wang, C., S. G. Kang, J. Lee, Z. Sun, and C. H. Kim. 2009. The roles of CCR6 in migration of Th17 cells and regulation of effector T-cell balance in the gut. Mucosal Immunol. 2: 173-183.
41. Sallusto, F., D. Impellizzieri, C. Basso, A. Laroni, A. Uccelli, A. Lanzavecchia, and B. Engelhardt. 2012. T-cell trafficking in the central nervous system. Immunol. Rev. 248: 216-227.
42. Reboldi, A., C. Coisne, D. Baumjohann, F. Benvenuto, D. Bottinelli, S. Lira, A. Uccelli, A. Lanzavecchia, B. Engelhardt, and F. Sallusto. 2009. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat. Immunol. 10: 514-523.
43. Macoska, J. A. 2011. Chemokines and BPH/LUTS. Differentiation 82: 253-260.
44. Liu, L., Q. Li, P. Han, X. Li, H. Zeng, Y. Zhu, and Q. Wei. 2009. Evaluation of interleukin-8 in expressed prostatic secretion as a reliable biomarker of inflammation in benign prostatic hyperplasia. Urology 74: 340-344.
45. Desireddi, N. V., P. L. Campbell, J. A. Stern, R. Sobkoviak, S. Chuai, S. Shahrara, P. Thumbikat, R. M. Pope, J. R. Landis, A. E. Koch, and A. J. Schaeffer. 2008. Monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha as possible biomarkers for the chronic pelvic pain syndrome. J. Urol. 179: 1857-1861, discussion 1861-1862.
46. Quick, M. L., S. Mukherjee, C. N. Rudick, J. D. Done, A. J. Schaeffer, and P. Thumbikat. 2012. CCL2 and CCL3 are essential mediators of pelvic pain in experimental autoimmune prostatitis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 303: R580-R589.